Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 10:13 PM ET

Pharmaceuticals

Company Overview of Hutchison MediPharma Limited

Company Overview

Hutchison MediPharma Limited, a drug development company, focuses on discovering, developing, and commercializing therapeutics for oncology and autoimmune diseases. Its product portfolio includes HMPL-004, an oral botanical product that acts on multiple targets in the pathogenesis of inflammatory bowel disease; Sulfatinib (HMPL-012), a small molecule that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor (VEGF) and fibroblast growth factor receptors; and Fruquintinib (HMPL-013), a small molecule compound that selectively inhibits VEGF receptors. The company’s product portfolio also includes Epitinib (HMPL-813), an orally active small molecul...

Building 4

917 Halei Road

Zhangjiang Hi-Tech Park

Pudong

Shanghai,  201203

China

Founded in 2002

Phone:

86 21 2067 3000

Fax:

86 21 2067 3186

Key Executives for Hutchison MediPharma Limited

Chief Scientific Officer and Executive Vice President of Drug Research
Head of Drug Metabolism & Pharmacokinetics and Vice President
Senior Vice President of Pharmaceutical Sciences
Senior Vice President and Head of Clinical Development & Regulatory Affairs
Head of Oncology Research and Vice President
Compensation as of Fiscal Year 2014.

Hutchison MediPharma Limited Key Developments

Hutchison China Meditech Announces Patient Enrolment Completion for Phase II Study

Chi-Med announced that Hutchison MediPharma Limited has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung cancer patients in China. The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors. This randomized, double-blind, placebo-controlled, multi-centre, POC Phase II study is targeted at treating non-squamous NSCLC patients who have failed second-line standard chemotherapy. A total of 91 patients have now been randomized to receive fruquintinib plus best supportive care or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in mid of 2015. Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib. Based on the Phase I data in colorectal cancer, a Phase Ib study was initiated which treated a further 62 CRC patients. Detailed results of the Phase Ib clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in May 2014. In April 2014, HMP initiated the first POC Phase II study, which was a randomized, double-blind, placebo-controlled, multi-centre Phase II clinical trial targeted at patients with metastatic CRC. The POC Phase II study subsequently completed enrolment in August 2014, and will report data during the first half of 2015. In October 2014, HMP initiated a Phase Ib dose-finding study of fruquintinib, in combination with paclitaxel, in second line gastric cancer patients. In December 2014, HMP initiated FRESCO, a Phase III registration study in patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineo-plastic therapies, including flouropyrimidine, oxaliplatin and irinotecan. FRESCO will enroll more than 400 patients in 25 centers in China, with top-line results expected in 2016.

Hutchison MediPharma Limited Announces Initiation of Fruquintinib Phase III Registration Study in Colorectal Cancer

Hutchison MediPharma Limited (HMP), has initiated FRESCO, a Phase III registration study in colorectal cancer (CRC) patients in China, for fruquintinib (HMPL-013), its investigational small molecule which selectively inhibits vascular endothelial growth factor receptors (VEGFR). Preparations and site selection began in the middle of this year, with the first patient dosed on 12 December 2014. This randomised, double-blind, placebo-controlled, multicentre, Phase III registration study is targeted at treating patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin and irinotecan. Patients will be randomised at a 2:1 ratio to receive either: 5 milligrams of fruquintinib orally once per day, on a three-weeks-on /one-week-off cycle, plus best supportive care (BSC); or placebo plus BSC. The primary endpoint is overall survival, with secondary endpoints including progression free survival, objective response rate, disease control rate and duration of response. More than 400 patients will be enrolled in about 25 centres, with top-line results expected in 2016. Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. At an advanced stage, tumours secrete large amounts of VEGF, a protein ligand, to stimulate formation of excessive vasculature (angiogenesis) around the tumour in order to provide greater blood flow, oxygen, and nutrients to the tumour. VEGF and VEGF receptors (VEGFRs) play a pivotal role in tumour -related angiogenesis, and inhibition of the VEGF/VEGFR pathway. This represents therapeutic strategy in blocking the development of new blood vessels essential for tumours to grow and invade. To date, several anti-VEGF/VEGFR agents have shown clinical efficacy against a number of tumour types. Given the scale and growth in the China oncology market, the market for VEGF/VEGFR inhibitors in China is expected to develop quickly in the next few years.

Hutchison Medipharma Limited Completes Patient Enrolment in Phase II Clinical Trial of Fruquintinib in Colorectal Cancer in China

Hutchison MediPharma Limited has completed patient enrolment in a Phase II clinical trial of fruquintinib in colorectal cancer in China. The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors. This randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept Phase II study is targeted at treating patients with metastatic CRC, who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan. A total of 71 patients have now been randomised to receive fruquintinib plus best supportive care or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in early 2015. Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hutchison MediPharma Limited, please visit www.hmplglobal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.